Track the Kailera Therapeutics, Inc. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Market capitalisation: €2.3bn. The latest transaction was filed on 22 April 2026 (Acquisition). Among the most active insiders: Bain Capital Life Sciences Investors, LLC. All data is openly available.
14
Insider Decl.
n/a
Thresholds
€277m
5 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Kailera Therapeutics, Inc. Strong Buy (bullish), based on 5 analysts. Average price target: US$42.40.
49Σ signal
Buys €277mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Kailera Therapeutics, Inc. es una empresa biofarmacéutica centrada en el desarrollo de terapias para enfermedades genéticas raras. Pone énfasis en la innovación en el campo de los tratamientos basados en la edición del genoma.